脳腫瘍治療薬市場：適応症別、治療法別、流通チャネル別、地域別、機会、予測、2017年～2031年

世界の脳腫瘍治療薬の市場規模は、2024年～2031年の予測期間中に8.53％のCAGRで拡大し、2023年の29億2,000万米ドルから2031年には56億2,000万米ドルに成長すると予測されています。脳腫瘍治療薬市場の成長は、研究活動への投資の増加、研究者への助成金の提供の増加、さまざまな規制機関からの承認の加速度的な増加、脳腫瘍の症例の増加、新規治療ソリューションの開発に向けた主要市場参入企業の努力の高まりによって支えられています。脳腫瘍治療薬には、免疫療法、標的療法、化学療法など幅広い治療オプションが含まれます。

様々な政府が脳腫瘍に関する認知度を高め、必要な治療法の利用可能性を確保するために積極的に投資しており、世界の脳腫瘍治療薬市場規模を押し上げています。例えば、カナダ政府は良性・悪性脳腫瘍患者のための新規治療法の開発に積極的に取り組んでいます。さらに、カナダ脳腫瘍財団やブレイン・カナダ財団などの組織との連携が、研究投資の効果を最大化する上で政府を支援しています。例えば、トロント大学とユニバーシティ・ヘルス・ネットワークの神経外科医・科学者は、脳腫瘍患者の臨床管理やリスクの高い外科手術を防ぐための新規治療法を変革することができました。

いくつかの市場関係者や製薬会社は、脳腫瘍の脅威の高まりに対抗するため、世界各国で規制が緩和され、承認プロセスが加速していることから、新規脳腫瘍治療法の開拓に積極的に投資しています。臨床試験の増加に伴い、新規治療法の着実な流れにより、市場は予測される数年間に有利な成長機会に遭遇すると予想されます。

当レポートでは、世界の脳腫瘍治療薬市場について調査し、市場の概要とともに、適応症別、治療法別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の脳腫瘍治療薬市場の見通し、2017年～2031年

• 市場規模の分析と予測
• 市場シェア分析と予測
• 市場マップ分析、2023年
  • 適応症別
  • 治療法別
  • 流通チャネル別
  • 地域別

第5章 北米の脳腫瘍治療薬市場の見通し、2017年～2031年

第6章 欧州の脳腫瘍治療薬市場の見通し、2017年～2031年

第7章 アジア太平洋の脳腫瘍治療薬市場の見通し、2017年～2031年

第8章 南米の脳腫瘍治療薬市場の見通し、2017年～2031年

第9章 中東・アフリカの脳腫瘍治療薬市場の見通し、2017年～2031年

第10章 需要供給分析

第11章 輸出入の分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

第17章 市場の動向と発展

第18章 規制枠組みとイノベーション

第19章 特許の情勢

第20章 ケーススタディ

第21章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要参入企業トップ10の情勢
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Novartis AG
  • Emcure Pharmaceuticals
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services, Inc.
  • GlaxoSmithKline plc
  • Amgen Inc.
  • AstraZeneca PLC

第22章 戦略的提言

第23章 お問い合わせと免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 2. Global Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 3. Global Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 4. Global Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 5. Global Brain Cancer Therapeutics Market Share (%), By Region, 2017-2031F
• Figure 6. North America Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 7. North America Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 8. North America Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 9. North America Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 10. North America Brain Cancer Therapeutics Market Share (%), By Country, 2017-2031F
• Figure 11. United States Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 12. United States Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 13. United States Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 14. United States Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 15. Canada Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 16. Canada Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 17. Canada Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 18. Canada Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 19. Mexico Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 20. Mexico Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 21. Mexico Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 22. Mexico Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 23. Europe Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 24. Europe Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 25. Europe Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 26. Europe Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 27. Europe Brain Cancer Therapeutics Market Share (%), By Country, 2017-2031F
• Figure 28. Germany Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 29. Germany Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 30. Germany Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 31. Germany Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 32. France Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 33. France Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 34. France Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 35. France Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 36. Italy Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 37. Italy Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 38. Italy Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 39. Italy Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 40. United Kingdom Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 41. United Kingdom Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 42. United Kingdom Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 43. United Kingdom Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 44. Russia Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 45. Russia Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 46. Russia Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 47. Russia Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 48. Netherlands Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 49. Netherlands Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 50. Netherlands Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 51. Netherlands Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 52. Spain Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 53. Spain Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 54. Spain Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 55. Spain Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 56. Turkey Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 57. Turkey Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 58. Turkey Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 59. Turkey Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 60. Poland Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 61. Poland Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 62. Poland Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 63. Poland Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 64. South America Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 65. South America Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 66. South America Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 67. South America Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 68. South America Brain Cancer Therapeutics Market Share (%), By Country, 2017-2031F
• Figure 69. Brazil Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 70. Brazil Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 71. Brazil Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 72. Brazil Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 73. Argentina Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 74. Argentina Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 75. Argentina Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 76. Argentina Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 77. Asia-Pacific Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 78. Asia-Pacific Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 79. Asia-Pacific Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 80. Asia-Pacific Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 81. Asia-Pacific Brain Cancer Therapeutics Market Share (%), By Country, 2017-2031F
• Figure 82. India Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 83. India Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 84. India Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 85. India Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 86. China Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 87. China Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 88. China Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 89. China Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 90. Japan Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 91. Japan Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 92. Japan Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 93. Japan Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 94. Australia Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 95. Australia Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 96. Australia Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 97. Australia Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 98. Vietnam Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 99. Vietnam Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 100. Vietnam Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 101. Vietnam Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 102. South Korea Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 103. South Korea Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 104. South Korea Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 105. South Korea Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 106. Indonesia Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 107. Indonesia Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 108. Indonesia Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 109. Indonesia Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 110. Philippines Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 111. Philippines Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 112. Philippines Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 113. Philippines Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 114. Middle East & Africa Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 115. Middle East & Africa Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 116. Middle East & Africa Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 117. Middle East & Africa Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 118. Middle East & Africa Brain Cancer Therapeutics Market Share (%), By Country, 2017-2031F
• Figure 119. Saudi Arabia Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 120. Saudi Arabia Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 121. Saudi Arabia Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 122. Saudi Arabia Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 123. UAE Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 124. UAE Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 125. UAE Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 126. UAE Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 127. South Africa Brain Cancer Therapeutics Market, By Value, In USD Billion, 2017-2031F
• Figure 128. South Africa Brain Cancer Therapeutics Market Share (%), By Indication, 2017-2031F
• Figure 129. South Africa Brain Cancer Therapeutics Market Share (%), By Therapy, 2017-2031F
• Figure 130. South Africa Brain Cancer Therapeutics Market Share (%), By Distribution Channel, 2017-2031F
• Figure 131. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 132. By Therapy Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global brain cancer therapeutics market is projected to witness a CAGR of 8.53% during the forecast period 2024-2031, growing from USD 2.92 billion in 2023 to USD 5.62 billion in 2031. The growth of the brain cancer therapeutics market is supported by the rising investments in research activities, increasing provision of grants to researchers, growing approvals from different regulatory bodies in an accelerated manner, rising cases of brain cancer, and growing efforts of the key market players towards the development of novel therapeutic solutions. Brain cancer therapeutics encompass a broad range of treatment options, such as immunotherapies, targeted therapies, and chemotherapies.

Various governments are actively investing in increasing awareness about brain cancer and ensuring the availability of required therapies, propelling the global brain cancer therapeutics market size. For instance, the government of Canada is actively working on developing novel treatments for patients with benign and malignant brain tumors. Additionally, collaborations with organizations, such as the Brain Tumor Foundation of Canada and the Brain Canada Foundation, are aiding the government in maximizing the impact of research investments. For instance, a neurosurgeon-scientist from the University of Toronto and the University Health Network was able to transform the clinical management of patients with brain tumors and novel therapies for preventing high-risk surgical procedures.

Several market players and pharmaceutical companies are actively investing in the development of novel brain cancer therapies due to regulatory relaxations and an accelerated process of approval in various countries across the globe to combat the rising threat of brain cancer. With the help of the increasing number of clinical trials, the market is expected to encounter lucrative growth opportunities in the forecast years due to the steady flow of novel therapies.

Rising Research Activities to Provide Growth Opportunities

The rising research activities and investments in experimental drugs for combatting the growing threat of brain cancer are providing lucrative growth opportunities to the market. An experimental treatment being pioneered at the University College London (UCL) by a team of brain cancer specialists has shown remarkable success in various patients with brain cancer and is expected to be available within the next five years. With the rising cases of brain cancer, various research organizations across the globe are working on developing novel therapies for treating and managing the condition and providing funding to promising candidates to accelerate the development of novel therapeutics. In September 2024, a researcher from the University of Galway received a European Research Council (ERC) grant of approximately USD 1.6 million for working on new treatments for brain cancer. The researcher successfully developed a soft gel that contains cancer fighting drug for improving the effectiveness of drug-radiation therapy by weakening cancer cells.

Increasing Regulatory Approvals to Support Market Expansion

The rising approvals by different regulatory bodies, including the Food and Drug Administration (FDA), for treating various types of brain tumors provide lucrative growth opportunities to the market. In August 2024, the US FDA approved a new drug for slowing the growth of low-grade diffuse gliomas. This approval represents the thirst for molecularly targeted therapy designed for the disease and the first new option for treating low-grade diffuse glioma in over twenty years. The clinical trials demonstrating the drug's potential were published first in 2023 in the New England Journal of Medicine.

Similarly, in April 2024, the FDA approved Tovorafenib for treating the most common childhood brain tumor. The FDA has approved the drug in an accelerated manner for patients who are six months or older with refractory or relapsed pediatric low-grade glioma (pLGG) harboring a BRAF V600 mutation or BRAF fusion or rearrangement. The goal of the treatment is to shrink or stabilize the tumor without disrupting the life of the family or the patient. Such approvals provide treatment options for types of brain cancer that previously did not have any aiding healthcare professionals in combating the disease.

Immunotherapy to Hold Significant Market Share

Immunotherapy approaches take advantage of the patient's immune system and aid in eliminating the cancer cells by activating and stimulating the immune system in a targeted manner to kill tumor cells. The increasing success of different immunotherapies over the past few years in patients with various types of cancer is bolstering the interest in the therapy for treating malignant gliomas. The increasing provision of grants and rewards for immunotherapy research in brain cancer provides lucrative growth opportunities to the market. In October 2023, the California Institute for Regenerative Medicine (CIRM) awarded approximately USD 12 million to a researcher for a phase 1 clinical trial for assessing the safety of CAR-T cell immunotherapy for the most common type of malignant primary brain tumor in adults, glioblastoma multiforme. Such supportive initiatives have allowed the inclusion of additional trial participants for consideration in the research study. The standard approaches can provide symptomatic relief. However, they have a limited impact on improving the overall survival rate. Due to the rising provision of rewards, researchers can develop novel therapeutic solutions to improve survival rates and identify potential treatment alternatives for previously untreatable types of brain tumors.

North America to Hold Major Market Share

The rapid expansion of the market in the region is supported by the prominent presence of significant market players and increasing cases of brain cancer. According to the estimates of the National Foundation for Cancer Research (NFCR), approximately 25,400 malignant tumors of the spinal cord and brain were diagnosed in 2024 in the United States. Additionally, the presence of a well-established healthcare system in countries such as the United States and Canada is also supporting the treatment, management, and diagnosis of complex conditions such as brain cancer. The presence of globally recognized clinics, hospitals, and treatment centers also ensures that patients have access to advanced diagnostic solutions and advanced diagnostic tools. Moreover, countries in North America are also allocating a significant portion of their healthcare budgets to the development and availability of advanced therapeutics to improve patient care. This increased spending allows for extensive research and development activities, propelling the availability of treatment options to enhance treatment outcomes for patients with brain cancer. Furthermore, the increasing efforts of government and private organizations to push awareness about brain cancer and treatment options available for the condition also provide lucrative growth opportunities to the market.

Future Market Scenario (2024 - 2031F)

The global brain cancer therapeutics market is expected to witness significant growth in the coming years due to the rising cases of brain cancer and increasing investment by various governments towards the development of the healthcare industry. As per the predictions of the World Health Organization (WHO), in the European region, approximately 85,000 new cases and 70,000 deaths from central nervous system and brain cancer are expected to occur in 2030. Additionally, increasing research activities by researchers across the globe are likely to support the expansion of the global brain cancer therapeutics market. For instance, City of Hope Medical Center, United States, is conducting an interventional study to assess if standard dose dexamethasone and low dose dexamethasone work in the same manner for reducing brain swelling after patients with brain cancer or primary brain tumors have undergone brain surgery. The study is expected to conclude in September 2025. Furthermore, developing a supportive regulatory environment is expected to encourage pharma companies to expedite the development of novel therapeutic solutions for brain cancer. Rising organizations' efforts to bolster brain cancer awareness are expected to augment the global brain cancer therapeutics market demand.

Key Players Landscape and Outlook

Increasing investments by the key market players toward novel product development and launches are aiding them in expanding their market reach and providing lucrative growth opportunities for the market. These efforts are helping the healthcare sector address the various gaps in the existing therapies and ensure the availability of advanced treatment solutions, improving patient survival rates and enhancing the effectiveness of treatments. Additionally, novel launches are often backed by speedy regulatory processes and approvals, ensuring quicker access to the market, and further encouraging market players to dedicate their resources to developing new therapeutic solutions. In March 2023, Novartis AG announced that the US FDA granted approval to Tafinlar + Mekinist for treating pediatric patients who are one year and older and suffering from low-grade glioma (LGG) with BRAF V600E mutation and require systemic therapy. This new indication holds the potential to become the new standard of treatment option for younger patients who are battling with this type of brain cancer. Novel launches by market players are crucial for driving the growth of the global brain cancer therapeutics market as new products continue to emerge, expected to enhance the treatment landscape for brain cancer and augment the market's expansion.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Brain Cancer Therapeutics Market Outlook, 2017-2031F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Indication
    • 4.2.1.1. Glioblastoma
    • 4.2.1.2. Meningioma
    • 4.2.1.3. Pituitary Tumor
    • 4.2.1.4. Others
  • 4.2.2. By Therapy
    • 4.2.2.1. Targeted Therapy
    • 4.2.2.2. Chemotherapy
    • 4.2.2.3. Immunotherapy
    • 4.2.2.4. Others
  • 4.2.3. By Distribution Channel
    • 4.2.3.1. Hospital Pharmacies
    • 4.2.3.2. Retail Pharmacies
    • 4.2.3.3. Online Pharmacies
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia-Pacific
    • 4.2.4.4. South America
    • 4.2.4.5. Middle East and Africa
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
• 4.3. Market Map Analysis, 2023
  • 4.3.1. By Indication
  • 4.3.2. By Therapy
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. North America Brain Cancer Therapeutics Market Outlook, 2017-2031F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Indication
    • 5.2.1.1. Glioblastoma
    • 5.2.1.2. Meningioma
    • 5.2.1.3. Pituitary Tumor
    • 5.2.1.4. Others
  • 5.2.2. By Therapy
    • 5.2.2.1. Targeted Therapy
    • 5.2.2.2. Chemotherapy
    • 5.2.2.3. Immunotherapy
    • 5.2.2.4. Others
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Hospital Pharmacies
    • 5.2.3.2. Retail Pharmacies
    • 5.2.3.3. Online Pharmacies
  • 5.2.4. By Country Share
    • 5.2.4.1. United States
    • 5.2.4.2. Canada
    • 5.2.4.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Brain Cancer Therapeutics Market Outlook, 2017-2031F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Indication
        • 5.3.1.2.1.1. Glioblastoma
        • 5.3.1.2.1.2. Meningioma
        • 5.3.1.2.1.3. Pituitary Tumor
        • 5.3.1.2.1.4. Others
      • 5.3.1.2.2. By Therapy
        • 5.3.1.2.2.1. Targeted Therapy
        • 5.3.1.2.2.2. Chemotherapy
        • 5.3.1.2.2.3. Immunotherapy
        • 5.3.1.2.2.4. Others
      • 5.3.1.2.3. By Distribution Channel
        • 5.3.1.2.3.1. Hospital Pharmacies
        • 5.3.1.2.3.2. Retail Pharmacies
        • 5.3.1.2.3.3. Online Pharmacies
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Brain Cancer Therapeutics Market Outlook, 2017-2031F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Brain Cancer Therapeutics Market Outlook, 2017-2031F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Brain Cancer Therapeutics Market Outlook, 2017-2031F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Brain Cancer Therapeutics Market Outlook, 2017-2031F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Import and Export Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

• 18.1. Clinical Trials
• 18.2. Regulatory Approvals

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

• 21.1. Competition Matrix of Top 5 Market Leaders
• 21.2. SWOT Analysis for Top 5 Players
• 21.3. Key Players Landscape for Top 10 Market Players
  • 21.3.1. Merck & Co., Inc.
    • 21.3.1.1. Company Details
    • 21.3.1.2. Key Management Personnel
    • 21.3.1.3. Products and Services
    • 21.3.1.4. Financials (As Reported)
    • 21.3.1.5. Key Market Focus and Geographical Presence
    • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 21.3.2. F. Hoffmann-La Roche Ltd
  • 21.3.3. Pfizer Inc.
  • 21.3.4. Novartis AG
  • 21.3.5. Emcure Pharmaceuticals
  • 21.3.6. Bristol-Myers Squibb Company
  • 21.3.7. Johnson & Johnson Services, Inc.
  • 21.3.8. GlaxoSmithKline plc
  • 21.3.9. Amgen Inc.
  • 21.3.10. AstraZeneca PLC

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer